Literature DB >> 8553585

In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus:cell interaction observed in nasopharyngeal carcinoma.

P G Knox1, Q X Li, A B Rickinson, L S Young.   

Abstract

The interaction of Epstein-Barr virus (EBV) with epithelial cells and the consequent role of the virus in the aetiology of undifferentiated nasopharyngeal carcinoma (NPC) is poorly understood. One important obstacle to work in this area has been the lack of an epithelial cell culture system in which EBV is stably maintained. Using a previously described approach in which CR2-transfected epithelial cells (SVK-CR2) are rendered susceptible to transient EBV infection (Li et al., Nature 356, 347, 1992), we now demonstrate that the pattern of EBV latent gene transcription in these acutely infected epithelial cells differs from that observed in virus-infected primary B cells. In addition, some of these epithelial cells spontaneously entered the EBV lytic cycle. By cloning Akata virus-infected SVK-CR2 cells we generated two stable lines which remained EBV positive for more than 1.5 years at which time further subclones were isolated. These cloned lines carry the EBV genome as an episome and exclusively use the FQp promoter for driving EBNA1 transcription, display no Cp/Wp promoter activity, and express low levels of the LMP mRNAs. Unlike acutely infected SVK-CR2 cells, the cloned lines responded poorly to suspension-induced terminal differentiation and were impaired in their ability to enter the virus lytic cycle. These results, showing similarities between the cloned EBV-positive SVK-CR2 lines and NPC tumour cells, suggest that stable maintenance of EBV in epithelial cells may require an undifferentiated cellular environment.

Entities:  

Mesh:

Year:  1996        PMID: 8553585     DOI: 10.1006/viro.1996.0005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  22 in total

1.  Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes.

Authors:  Y Chang; C H Tung; Y T Huang; J Lu; J Y Chen; C H Tsai
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

Review 3.  The expression and function of Epstein-Barr virus encoded latent genes.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Mol Pathol       Date:  2000-10

Review 4.  Epstein-Barr virus and gastric carcinoma.

Authors:  K Takada
Journal:  Mol Pathol       Date:  2000-10

5.  CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.

Authors:  J D Fingeroth; M E Diamond; D R Sage; J Hayman; J L Yates
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells.

Authors:  S Imai; J Nishikawa; K Takada
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 7.  Epstein-Barr virus infection and human malignancies.

Authors:  G Niedobitek; N Meru; H J Delecluse
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

8.  The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5.

Authors:  R Tierney; H Kirby; J Nagra; A Rickinson; A Bell
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  Multiple pathways for Epstein-Barr virus episome loss from nasopharyngeal carcinoma.

Authors:  Dirk P Dittmer; Chelsey J Hilscher; Margaret L Gulley; Eric V Yang; Min Chen; Ronald Glaser
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

10.  Features distinguishing Epstein-Barr virus infections of epithelial cells and B cells: viral genome expression, genome maintenance, and genome amplification.

Authors:  Claire Shannon-Lowe; Emily Adland; Andrew I Bell; Henri-Jacques Delecluse; Alan B Rickinson; Martin Rowe
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.